He Rong Technology New Stock Subscription Analysis: A high-end medical technology company focused on boron neutron capture therapy.

robot
Abstract generation in progress

Horizon Technology (7799) will open for public subscription from September 3 to 5, and plans to list on the Taiwan Stock Exchange on September 15. As a high-tech medical company focusing on accelerator-based boron neutron capture therapy (AB-BNCT), Horizon Technology's listing has attracted significant market attention.

Core Advantages of the Company

He Rong Technology integrates key patents and technologies from Tsinghua University and the Industrial Technology Research Institute, providing comprehensive solutions ranging from site assessment, radiation shielding planning to the implementation of treatment planning systems. The company has received a 1.2 billion NT dollar order from Taipei Veterans General Hospital's AB-BNCT treatment center, expected to be completed and recognized as revenue by 2027, bringing significant growth momentum for future operations.

Research and Industry-Academia Collaboration

Horizon Technology announced on September 2nd the signing of a cooperation agreement with Tsinghua University to jointly establish the "Horizon-Tsinghua Joint Research and Development Center". This move not only strengthens the research and development capabilities of advanced medical technologies such as AB-BNCT but also promotes the practical application of innovative achievements, becoming an important model for industry-academia collaboration.

Subscription Details and Market Performance

  • Public offering number of shares: 2843 shares
  • Purchase limit per person: 1
  • Draw date: September 9th, morning
  • Lottery result inquiry: Before 12 PM on September 9
  • Refund date (for those who did not win the lottery): September 10
  • Stock delivery date (for lottery winners): Before 8:30 AM on September 15

Based on the closing price of 849 TWD on September 2, compared to the underwriting price of 600 TWD, the price difference per share reaches 249 TWD. During trading on September 3, the stock price of He Rong Technology reached a maximum of 861 TWD, an increase of 1.41%, reflecting the market's continued optimism about its performance after listing.

Market Positioning and Future Development

He Rong Technology not only occupies a leading position in the AB-BNCT field but also independently develops the boron neutron capture therapy drug BPA, which is expected to obtain drug certification in 2027. This will further strengthen the company's revenue stability and market competitiveness, giving it greater advantages in the high-end medical technology field.

This article is for reference only and does not constitute any investment advice. Investors should fully understand the relevant risks and seek the advice of professional financial advisors before making investment decisions.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments